Tuesday, September 29, 2026 4:09 AM ET
2 days ago
Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s3 days ago
NIH cuts delayed a cancer trial. Patients lost time they didn't have3 days ago
Why we like Starbucks' latest turnaround move — plus, two more wins for Eli Lilly4 days ago
Novo's new strategy hinges on something it can't manufacture: investor trust5 days ago
Trump administration removes around 760,000 Obamacare enrollments5 days ago
Eli Lilly CEO says 700,000 seniors have started GLP-1s after Medicare coverage6 days ago
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo7 days ago
Why more companies are fighting over beauty, health and wellness spending7 days ago
Mitch McConnell returns to Senate after three-month health absence14 days ago
Athletes with autism take center court at the US Open14 days ago
Novo CEO tells CNBC why drugmaker is rebranding, needs to 'rethink' strategy14 days ago
Record U.S. cyclosporiasis outbreak is over, CDC says17 days ago
A rapid-fire update on our 33-stock portfolio, including 6 stocks to buy now17 days ago
Rare disease is taking his vision. A gene therapy could help — if he can get it18 days ago
Jim Cramer says investors are too focused on AI stocks. Here's where he says to look instead20 days ago
'Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threat20 days ago
AstraZeneca's COPD drug shows late-stage trial wins, boosts blockbuster hopes20 days ago
Pharma major Novartis falls 10% after three drug trial setbacks20 days ago
Cholesterol drug setback casts doubt over multibillion-dollar race21 days ago
Billionaire family offices back healthcare and biotech startups in August25 days ago
Cramer: Here are 3 defensive stock market moves I'm making as oil and rates surge27 days ago
We're adding 2 stocks to our Bullpen watchlist because they meet these criteria27 days ago
This medical device stock looks like a gift for patient investors27 days ago
August was the month of the comeback kids. Cramer reviews what drove the biggest winners28 days ago
Trump strikes new drug pricing deals with nine midsized drugmakers28 days ago
BioCryst is profitable. Now it wants to buy more rare disease drugs1 month ago
How Taylor Farms became integral to America's food supply system1 month ago
FDA approves daily HIV pill from Gilead designed to simplify treatment1 month ago
HHS plans new FDA leadership roles for technology and drugs, sources say1 month ago
Why vaccination rates are falling in the U.S.1 month ago
BioMarin to acquire Alesta Therapeutics for $275 million1 month ago